Private Equity, VC & Investor
Breega vs Korelya Capital
Structured technology and market comparison · 2026
Direct Feature Comparison
Breega · vs · Korelya CapitalEuropean and African early-stage venture capital fund manager.
Venture and growth equity investor in European technology companies.
Analyze all overlapping signals and tech stacks for Breega and Korelya Capital
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Breega and Korelya Capital?
When comparing Breega and Korelya Capital, both platforms operate within the Private Equity, VC & Investor ecosystem. Breega is positioned as European and African early-stage venture capital fund manager, whereas Korelya Capital focuses on Venture and growth equity investor in European technology companies. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Breega and Korelya Capital?
When evaluating Breega and Korelya Capital, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Breega and Korelya Capital compare?
Breega is headquartered in FR (founded in 2013) with 10–49 employees. Korelya Capital is based in FR (founded in 2016) with <10 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Breega vs Korelya Capital
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Breega
Recent Signals
- ·EU-Startups (European Venture)Funding
Cori Clinical Raises €3.8M to Accelerate Clinical Trials
London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.
- Cori Clinical raised €3.8 million in a Seed round led by Breega.
- Participants include Enzo, Heartfelt, Together Ventures, and Bynd.
- Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health.
Korelya Capital
Recent Signals
No recent market signals documented for Korelya Capital in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Breega and Korelya Capital share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks